Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Imbruvica (ibrutinib): where help paying exists, what Medicare negotiated and what pharmacies pay
Medicare's negotiated price for a 30-day supply is $9,319 (in force since January 1, 2026). A scheduled change takes it to $9,571 on January 1, 2027. ClinicalTrials.gov lists 30 recruiting trials that name ibrutinib.
Every package we can price
Per-unit prices (per unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 57962-0007-12 | IMBRUVICA (ibrutinib) 70mg/mL Oral Suspension | n/a | $59.13 | $60.73 | n/a | no NADAC price |
| 57962-0014-28 | IMBRUVICA (ibrutinib) 140mg Tablets 28 ct. | n/a | $354 | $364 | n/a | no NADAC price |
| 57962-0070-28 | IMBRUVICA (ibrutinib) 70mg Capsules 28 ct. | n/a | $354 | $364 | n/a | no NADAC price |
| 57962-0140-09 | IMBRUVICA (ibrutinib) 140mg 90 ct. | n/a | $118 | $121 | n/a | no NADAC price |
| 57962-0140-12 | IMBRUVICA (ibrutinib) 140mg 120 ct. | n/a | $118 | $121 | n/a | no NADAC price |
| 57962-0280-28 | IMBRUVICA (ibrutinib) 280mg Tablets 28 ct. | n/a | $354 | $364 | n/a | no NADAC price |
| 57962-0420-28 | IMBRUVICA (ibrutinib) 420mg Tablets 28 ct. | n/a | $354 | $364 | n/a | no NADAC price |
| 57962-0560-28 | IMBRUVICA (ibrutinib) 560mg Tablets 28 ct. | n/a | $354 | $364 | n/a | no NADAC price |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA205552 | Imbruvica (ibrutinib) 140mg 120 Ct., Imbruvica (ibrutinib) 140mg 90 Ct., Imbruvica (ibrutinib) 70mg Capsules 28 Ct. | April 24, 2035 | February 24, 2030 | April 24, 2035 | patent 10463668 with its pediatric extension; 140 dated entries listed |
| NDA210563 | Imbruvica (ibrutinib) 140mg Tablets 28 Ct., Imbruvica (ibrutinib) 280mg Tablets 28 Ct., Imbruvica (ibrutinib) 420mg Tablets 28 Ct. | September 3, 2036 | February 24, 2030 | September 3, 2036 | patent 10010507 with its pediatric extension; 286 dated entries listed |
| NDA217003 | Imbruvica (ibrutinib) 70mg/ml Oral Suspension | June 14, 2039 | February 24, 2030 | June 14, 2039 | patent 12201690; 50 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Imbruvica of $2.27 billion in 2024, across 146,416 claims and 15,351 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $2.27 billion | 146,416 | 15,351 | $15,478 |
| 2023 | $2.37 billion | 152,032 | 17,100 | $15,601 |
| 2022 | $2.85 billion | 195,679 | 22,202 | $14,585 |
| 2021 | $3.15 billion | 230,990 | 26,044 | $13,638 |
| 2020 | $2.96 billion | 232,858 | 26,847 | $12,724 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 17 designations for ibrutinib, 11 with an approval recorded. The 6 most recent are shown. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| February 1, 2018 | Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma | Designated | Pharmacyclics, LLC |
| June 12, 2017 | Treatment of pancreatic cancer | Designated | Pharmacyclics, LLC |
| June 23, 2016 | Treatment of chronic Graft versus Host disease | Designated/Approved | Pharmacyclics, LLC |
| June 23, 2016 | Treatment of chronic Graft versus Host disease | Designated/Approved | Pharmacyclics, LLC |
| February 2, 2016 | Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma) | Designated/Approved | Pharmacyclics, LLC |
| February 5, 2015 | Treatment of nodal marginal zone lymphoma | Designated/Approved | Pharmacyclics, LLC |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 2 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 108 | $1,454,673 | All record types |
| NJ | 55 | $550,763 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (1 state and package figure is marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 29 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated October 21, 2025 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 30 interventional trials that name ibrutinib and are recruiting, and 6 more not yet recruiting. By phase: Phase 2: 13, PHASE1/PHASE2: 9, Phase 1: 3, Phase 3: 3, Not applicable: 1, PHASE2/PHASE3: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT05998642 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaNon-hodgkin Lymphoma | Phase 2 | Canadian Cancer Trials Group | November 6, 2026 | Canada |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 2 | National Cancer Institute (NCI) | November 6, 2026 | United States |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaLymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | National Cancer Institute (NCI) | November 5, 2026 | United States |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerEpendymoma; Medulloblastoma; Glioblastoma | Phase 1 | Theodore S. Johnson | November 2, 2026 | United States |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaLymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia | Phase 2 | National Cancer Institute (NCI) | October 30, 2026 | United States |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | Phase 2 | VA Office of Research and Development | October 30, 2026 | United States |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSLPrimary Central Nervous System Lymphoma; Recurrent Cancer; Refractory Cancer | Phase 1 / Phase 2 | Dana-Farber Cancer Institute | October 21, 2026 | United States |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | Phase 3 | Merck Sharp & Dohme LLC | October 13, 2026 | United States, Australia, Belgium and 7 more |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)Chronic Graft-versus-host-disease | Phase 2 | Incyte Corporation | October 9, 2026 | United States, Belgium, Germany and 3 more |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Curis, Inc. | October 6, 2026 | United States, Czechia, France and 4 more |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Imbruvica?
For a 30-day supply the price CMS published is $9,319, in force since January 1, 2026. The CMS file also schedules $9,571 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Imbruvica?
No program in our finder lists this drug yet.
When could a generic version of Imbruvica arrive?
For Imbruvica, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA205552, April 24, 2035; NDA210563, September 3, 2036; NDA217003, June 14, 2039. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Imbruvica?
ClinicalTrials.gov lists 30 recruiting interventional trials that name ibrutinib (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Imbruvica?
CMS's Medicare Part D spending dataset reports gross spending on Imbruvica of $2.27 billion in 2024, across 146,416 claims and 15,351 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/imbruvica.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.